Do atherosclerosis and type 2 diabetes share a common inflammatory basis?

European Heart Journal

Volumn 23, Issue 11, 2002, Pages 831-834

  Pradhan, A D ^a   Ridker, P M ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATHEROGENESIS; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; DIABETOGENESIS; EDITORIAL; HUMAN; INFLAMMATORY DISEASE; ISCHEMIC HEART DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL;

ARTERIOSCLEROSIS; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS, TYPE 2; HUMANS; INFLAMMATION; INSULIN RESISTANCE; INTERLEUKIN-6; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0036294201     PISSN: 0195668X     EISSN: None     Source Type: Journal    
DOI: 10.1053/euhj.2001.3052     Document Type: Editorial

References (40)

1. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates, and projections
2. Diabetes and cardiovascular disease. The 'common soil' hypothesis
3. Is type II diabetes mellitus a disease of the innate immune system?
4. Insulin resistance and inflammation in an evolutionary perspective: The contribution of cytokine genotype/phenotype to thriftiness
5. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III)
6. High-sensitivity C-reactive protein: Potential adjunct for global risk assessment in the primary prevention of cardiovascular disease
7. Structure and function of the pentraxins
8. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein
9. Direct proinflammatory effect of C-reactive protein on human endothelial cells
10. Modulation of C-reactive protein-mediated monocyte chemoattractant protein-I induction in human endothelial cells by anti-atherosclerosis drugs
11. C-reactive proteinmediated low density lipoprotein uptake by macrophages: Implications for atherosclerosis
12. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina
13. Production of C-reactive protein and risk of coronary events in stable and unstable angina
14. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
15. C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: Results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992
16. Relationship of C-reactive protein to risk of cardiovascular disease in the elderly Results from the Cardiovascular Health Study and the Rural Health Promotion Project
17. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women
18. Low grade inflammation and coronary heart disease: Prospective study and updated meta-analyses
19. Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels
20. C-reactive protein adds to the predictive value of total and HDL cholesterol in determining risk of first myocardial infarction
21. Effect of statin therapy on C-reactive protein levels: The pravastatin inflammation/CRP evaluation (PRINCE): A randomised trial and cohort study
22. Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events
23. C-reactive protein in healthy subjects: Associations with obesity, insulin resistance, and endothelial dysfunction: A potential role for cytokines originating from adipose tissue?
24. Associations of C-reactive protein with measures of obesity, insulin resistance, and subclinical atherosclerosis in healthy, middle-aged women
25. Chronic subclinical inflammation as part of the insulin resistance syndrome: The Insulin Resistance Atherosclerosis Study (IRAS)
26. Interleukin-6 affects insulin secretion and glucose metabolism of rat pancreatic islets in vivo
27. Interleukin 1beta and interleukin 6, but not tumor necrosis factor alpha, inhibit insulin-stimulated glycogen synthesis in rat hepatocytes
28. Dose-dependent effects of recombinant human interleukin-6 on glucose regulation
29. Tumor necrosis factor alpha: A key component of the obesity-diabetes link
30. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities study): A cohort study
31. Factor VIII and other hemostasis variables are related to incident diabetes in adults. The Atherosclerosis Risk in Communities (ARIC) Study
32. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus
33. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo
34. Endothelial dysfunction: Cause of the insulin resistance syndrome
35. Acute systemic inflammation impairs endothelium-dependent dilatation in humans
36. Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial
37. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients
38. Pravastatin and the development of diabetes mellitus: Evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study
39. Expression of angiotensin II and interleukin 6 in human coronary atherosclerotic plaques: Potential implications for inflammation and plaque instability
40. Neopterin, tumor necrosis factor, C-reactive protein, and prostaglandin E2 in patients with severe congestive heart failure treated with enalapril